PerkinElmer Announces Collaboration with China's National Center for Drug Screening - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PerkinElmer Announces Collaboration with China's National Center for Drug Screening


PerkinElmer will collaborate with the National Center for Drug Screening (NCDS) to advance personalized medicine and drug profiling in China, the company announced in a press release. The two organizations will share knowledge, expertise, and innovative capabilities to establish a personalized drug research and development platform that will validate biomarkers for individualized disease treatment for Chinese patients.


The program will include sequencing patient samples in order to establish genomic information for drug profiling, including validation of biomarkers for personalized disease treatment and related informatics solutions. As a part of this program, PerkinElmer and NCDS will first undertake a study on metabolic diseases to validate new diagnostics for the Chinese populations through utilizing next-generation sequencing technologies. Once optimized, the technology platform will be implemented in testing laboratories and hospitals throughout China.

NCDS is a joint program of China’s Ministry of Science and Technology, the Chinese Academy of Sciences, and the Shanghai municipality government. At present, it is the only national center specializing in screening for new drugs. As a public technology platform, the Center offers drug-screening services and technical consultation to universities, research institutions, and pharmaceutical companies in China.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here